Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ASP015K

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Two randomized, double-blind, placebo-controlled studies are reported that had the objective to evaluate the pharmacokinetics… Expand
Is this relevant?
2015
2015
Abstract 1. The human mass balance of 14C-labelled ASP015K ([14C]ASP015K), an orally bioavailable Janus kinase (JAK) inhibitor… Expand
Is this relevant?
2015
2015
BACKGROUND Many immune-mediated disorders, including psoriasis, involve cytokine signalling via Janus kinase (JAK) enzymes… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
Abstract 1. Although marked gender differences have been reported for the exposure level of the sulfate metabolite M2 of ASP015K… Expand
Is this relevant?
2014
2014
Background ASP015K is a novel oral Janus kinase (JAK) inhibitor in development for the treatment of rheumatoid arthritis (RA… Expand
Is this relevant?
2013
2013
Background ASP015K is an oral Janus kinase (JAK) inhibitor with selectivity for JAK1/3 in development for treatment of rheumatoid… Expand
Is this relevant?
2013
2013
Background The Janus kinase (JAK) family of enzymes plays a key role in cytokine signaling, which is involved in the pathogenic… Expand
Is this relevant?
2013
2013
Background ASP015K is an oral Janus kinase (JAK) inhibitor of JAK1/3 in development for treatment of autoimmune diseases (eg… Expand
Is this relevant?
2013
2013
Background ASP015K is an oral Janus kinase (JAK) inhibitor with moderate selectivity for JAK3, a key enzyme for interleukin-2 (IL… Expand
Is this relevant?
2013
2013
Background Janus kinase (JAK) enzymes play key roles in cytokine signaling and are important in the pathology of autoimmune… Expand
Is this relevant?